Enhertu Approved for HER2-Positive Inoperable or Metastatic Cancer in Japan

Enhertu Approved for HER2-Positive Inoperable or Metastatic Cancer in Japan
Enhertu (trastuzumab deruxtecan) has been approved in Japan to treat adults with HER2-positive inoperable or metastatic breast cancer that is resistant to chemotherapy, or those who cannot tolerate it.  Enhertu is an antibody-drug conjugate (ADC) made up of the anti-HER2 antibody trastuzumab bound to the cancer-killing compound deruxtecan (a derivative of exatecan). HER2 is a protein found on the surface of about 1 in every 5 breast cancers. The presence of HER2-positive cancer cells is linked to an aggressive form of the disease, and a poorer prognosis for patients. Developed by Daiichi Sankyo and AstraZeneca, the therapy has been designed to deliver deruxtecan directly to HER2-positive cancer cells, allowing for greater specificity and reducing off-target effects compared to conventional chemother
Subscribe or to access all post and page content.